Aclaris Therapeutics, Inc. - ACRS
Ownership (Schedule 13D / 13G) · latest 50 filings
· Back to all files
Visible: 0
| Filed | Form | Reporting person | Percent | Shares | SEC |
|---|---|---|---|---|---|
| Apr 07, 2026 | SCHEDULE 13G | RA Capital Management, L.P. | 6.3% | 7,626,705 | View |
| Apr 07, 2026 | SCHEDULE 13G | Peter Kolchinsky | 6.3% | 7,626,705 | View |
| Apr 07, 2026 | SCHEDULE 13G | Rajeev Shah | 6.3% | 7,626,705 | View |
| Apr 07, 2026 | SCHEDULE 13G | RA Capital Healthcare Fund, L.P. | 6.3% | 7,626,705 | View |
| Mar 26, 2026 | SCHEDULE 13G/A | The Vanguard Group | 0.0% | 0 | View |
| Mar 17, 2026 | SCHEDULE 13G | Deep Track Capital, LP | 7.0% | 9,345,000 | View |
| Mar 17, 2026 | SCHEDULE 13G | Deep Track Biotechnology Master Fund, Ltd. | 7.0% | 9,345,000 | View |
| Mar 17, 2026 | SCHEDULE 13G | David Kroin | 7.0% | 9,345,000 | View |
| Feb 09, 2026 | SCHEDULE 13G/A | BML Investment Partners, L.P. | 11.9% | 14,250,000 | View |
| Jan 21, 2026 | SCHEDULE 13G/A | BlackRock, Inc. | 6.2% | 6,700,629 | View |
| Jan 09, 2026 | SCHEDULE 13G/A | Biosion, Inc. | 9.4% | 11,281,950 | View |
| Jan 09, 2026 | SCHEDULE 13G/A | Bonita Biotech (HK) Ltd | 9.4% | 11,281,950 | View |
| Nov 13, 2025 | SCHEDULE 13G/A | Adage Capital Management, L.P. | 4.87% | 5,278,144 | View |
| Nov 13, 2025 | SCHEDULE 13G/A | Robert Atchinson | 4.87% | 5,278,144 | View |
| Nov 13, 2025 | SCHEDULE 13G/A | Phillip Gross | 4.87% | 5,278,144 | View |
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G.
Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F).
Amendments (/A) can repeat the same holder over time, so rows should not be summed.
Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.